Cardiovascular disease risk factors: epidemiology and risk assessment

The American Journal of Cardiology
Björn Dahlöf

Abstract

Current epidemiologic predictions show that the world is heading for a vascular tsunami of pandemic proportions. The number of people at high risk from cardiovascular disease is increasing; recent cohort studies suggest that only 2%-7% of the general population have no risk factors at all, and >70% of at-risk individuals have multiple risk factors. The recently published Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) study, which showed that telmisartan was as effective as ramipril in the prevention of a range of cardiovascular outcomes, enrolled a broad cross section of high-risk patients. This population was chosen to reflect the type of patients encountered in general practice, and because the proportion of high-risk individuals is increasing worldwide, the ONTARGET results will be relevant for most at-risk patients. Further analysis of the ONTARGET results may also aid in the development of risk estimation scores populated with real-life data and could also determine the impact of treatment on the long-term reduction of total cardiovascular burden (ie, absolute risk reduction). This may be a particularly useful exercise because current risk estimation charts have limitations in t...Continue Reading

Associated Clinical Trials

References

Feb 1, 1976·The American Journal of Cardiology·W B Kannel
Mar 1, 1985·International Journal of Epidemiology·G Rose
May 21, 1999·Archives of Internal Medicine·P W WilsonR B D'Agostino
Nov 5, 1999·JAMA : the Journal of the American Medical Association·A H MokdadJ P Koplan
Sep 8, 2000·Diabetes Care·A H MokdadJ S Marks
Sep 18, 2001·JAMA : the Journal of the American Medical Association·A H MokdadJ P Koplan
Nov 9, 2002·Lancet·Majid EzzatiUNKNOWN Comparative Risk Assessment Collaborating Group
Dec 31, 2002·JAMA : the Journal of the American Medical Association·Ali H MokdadJames S Marks
Jun 6, 2003·European Heart Journal·R M ConroyUNKNOWN SCORE project group
Aug 2, 2003·Lancet·Majid EzzatiUNKNOWN Comparative Risk Assessment Collaborating Group
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Apr 27, 2004·Journal of Hypertension·Giuseppe ManciaCristina Giannattasio
Sep 29, 2004·Diabetes Care·Earl S FordAli H Mokdad
Jan 18, 2005·Lancet·Patricia M KearneyJiang He
Jan 13, 2006·JAMA : the Journal of the American Medical Association·Deepak L BhattUNKNOWN REACH Registry Investigators
Jan 13, 2006·Circulation·Thomas ThomUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Nov 7, 2006·Experimental Physiology·Robert Wolk, Virend K Somers
Nov 28, 2006·The European Journal of General Practice·Ian M Graham
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson

❮ Previous
Next ❯

Citations

Nov 9, 2010·Current Atherosclerosis Reports·Esad Vucic, Robert S Rosenson
Feb 16, 2011·Nature Immunology·Göran K Hansson, Andreas Hermansson
May 12, 2012·Mediators of Inflammation·Ting GuiYasuteru Muragaki
Jan 5, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Andrew C NewmanChristopher C W Hughes
Nov 28, 2012·International Journal of Nanomedicine·David A StoutThomas J Webster
Sep 10, 2010·International Journal of Medical Sciences·Ramin GhazizadehMohammad Ghazizadeh
Feb 3, 2012·Biomarkers in Medicine·Jacco C KarperPaul H A Quax
Nov 21, 2013·Trends in Endocrinology and Metabolism : TEM·Abdoulaye Sene, Rajendra S Apte
Nov 28, 2013·Annual Review of Physiology·Jorge Henao-MejiaRichard A Flavell
Sep 12, 2013·Future Cardiology·Angelos Halaris
Jan 25, 2014·Scientifica·Federico Carbone, Fabrizio Montecucco
May 6, 2014·Heart & Lung : the Journal of Critical Care·Kelly FlanneryTara L McMullen
Apr 29, 2014·European Journal of Pharmacology·Thomas P RoddyDouglas G Johns
Feb 18, 2016·The Journal of Nutritional Biochemistry·Rosa Vázquez-FresnoCristina Andres-Lacueva
Apr 11, 2013·Expert Review of Cardiovascular Therapy·Louise G H GohPhillip R Della
Sep 21, 2013·Critical Reviews in Biotechnology·Aydin BerenjianFariba Dehghani
Jul 29, 2011·Trends in Pharmacological Sciences·Maria Carmen MartinezRamaroson Andriantsitohaina
Dec 3, 2014·Journal of Atherosclerosis and Thrombosis·Masako NishikawaYutaka Yatomi
Dec 22, 2011·Thrombosis and Haemostasis·Bernhard Metzler, Bernhard Winkler
Oct 4, 2011·The Journal of Surgical Research·Alice B RezendeHenrique C Teixeira
Jul 14, 2011·Oral Diseases·O A GonzálezM J Novak
Jul 17, 2013·Journal of Thrombosis and Haemostasis : JTH·R LacroixF Dignat-George
Aug 10, 2011·Nursing in Critical Care·Konstantinos GiakoumidakisHero Brokalaki
Nov 21, 2013·Journal of Periodontal Research·W M MachadoD Fernandes
Sep 16, 2015·The Journal of General Physiology·Gema Ruiz-HurtadoAna María Gómez
Jul 16, 2015·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Emiel P C van der VorstChristian Weber
Jan 31, 2015·Sleep Medicine·Irina VirtanenPäivi Polo-Kantola
Dec 30, 2014·Atherosclerosis·Gareth W JonesBrendan J Jenkins
Nov 15, 2011·Expert Opinion on Pharmacotherapy·Maurizio DestroEmilio Galli
Jul 15, 2015·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Ammar W AshorJohn C Mathers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

© 2021 Meta ULC. All rights reserved